argenx Says Autoimmune Myositis Drug Meets Main Goal in Phase 3 Study
MT Newswires Live
Aug 17
argenx (ARGX) said a phase 3 study evaluating its experimental drug, Vyvgart Hytrulo, in adults with autoimmune myositis met main goal.
The company said the patients treated with the drug showed a statistically significant improvement in mean total improvement score at week 52 compared with placebo.
Treatment benefits emerged as early as week 4 and were sustained through the 52-week treatment period, including during steroid tapering, the company said.
argenx said the primary endpoint was also met in patients with immune-mediated necrotizing myopathy, while dermatomyositis patients showed a similar improvement, although it did not reach statistical significance.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.